Autres langues Ligand Pharmaceuticals Incorporated

Actions

LGND

US53220K5048

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 28/09/2026			Varia. 5j.	Varia. 1 janv.
314,10 ^USD	+4,17%		+10,80%	+66,13%

25/09	Ligand Pharmaceuticals Incorporated : Barclays relève sa recommandation à acheter	ZM
24/09	Ligand Pharmaceuticals investit jusqu’à 47 millions de dollars dans AvenCell	MT

Autres langues

24/09	Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell
24/09	Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
24/09	AvenCell Therapeutics, Inc. announced that it expects to receive $6 million in funding from Ligand Pharmaceuticals Incorporated
22/09	Primrose Bio, Inc. announced that it has received $20.999998 million in funding from 1315 Capital, LLC, Agent Capital, LLC, LDV Partners, Ligand Pharmaceuticals Incorporated, Signet Healthcare Partners
22/09	Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million
22/09	Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
16/09	Primrose Bio, Inc. announced that it expects to receive $20.999998 million in funding
09/09	Ligand Pharmaceuticals Insider Sold Shares Worth $1,430,434, According to a Recent SEC Filing
26/08	Ligand to Participate in September Investor Conferences
07/08	Tranche Update on Ligand Pharmaceuticals Incorporated's Equity Buyback Plan announced on August 8, 2023.
06/08	Ligand Pharmaceuticals Reaffirms Earnings Guidance for the Year 2026
06/08	Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed
06/08	(LGND) Ligand Pharmaceuticals Expects 2026 Revenue Range $270M - $310M, vs. FactSet Est of $287.4M
06/08	(LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $9.00 to $9.50, vs. FactSet Est of $9.21
06/08	Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Reports Q2 Revenue $63.7M, vs. FactSet Est of $60.9M
06/08	Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Posts Q2 Adjusted EPS $2.37 per Share, vs. FactSet Est of $1.95
06/08	Ligand: Q2 Earnings Snapshot
06/08	Ligand Reports Second Quarter 2026 Financial Results
05/08	Ligand Pharmaceuticals Insider Sold Shares Worth $1,444,951, According to a Recent SEC Filing
23/07	Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
15/07	Agenus Inc. announced that it has received $85 million in funding from RA Capital Management, L.P., Ligand Pharmaceuticals Incorporated, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Investment Arm
14/07	Ligand Pharmaceuticals Incorporated completed the acquisition of XOMA Royalty Corporation from a group of shareholders.
14/07	Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase
14/07	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets